Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Weighted Average and Diluted) (2022 - 2025)

Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.34 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 60.92% year-over-year to -$0.34; the TTM value through Sep 2025 reached -$1.78, up 61.72%, while the annual FY2024 figure was -$4.67, 24.53% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.34 at Insight Molecular Diagnostics, down from -$0.31 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.4 in Q1 2023 and bottomed at -$8.03 in Q4 2022.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.87 (2024), against an average of -$1.52.
  • The largest annual shift saw EPS (Weighted Average and Diluted) skyrocketed 1100.0% in 2023 before it tumbled 382.5% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$8.03 in 2022, then surged by 71.48% to -$2.29 in 2023, then dropped by 12.34% to -$2.57 in 2024, then skyrocketed by 86.78% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's EPS (Weighted Average and Diluted) are -$0.34 (Q3 2025), -$0.31 (Q2 2025), and -$0.26 (Q1 2025).